Table 2 Liver metastases-related characteristics in 30 patients with liver metastases from Nasopharyngeal Carcinoma
| Â | Resection group | Control group | P value |
|---|---|---|---|
|  | (n = 15) | (n = 15) |  |
Lesion numbers | Â | Â | >0.999 |
 <3 | 12 (80%) | 11 (73.3%) |  |
 ≥3 | 3 (20%) | 4 (26.7%) |  |
Size of largest metastasis (cm) | Â | Â | 0.450 |
 <5 | 8 (53.3%) | 11 (73.3%) |  |
 ≥5 | 7 (46.7%) | 4 (26.7%) |  |
Pathological type | Â | Â | >0.999 |
 Undifferentiated | 15 (100%) | 15 (100%) |  |
 Other types | 0 (0%) | 0 (0%) |  |
Dose of Primary Radiotherapy (Gy) | Â | Â | >0.999 |
 Nasopharyngeal | 70 (68–76) | 70 (66–78) |  |
 Regional lymph nodes | 66 (50–68) | 64 (50–70) |  |
Adjuvant chemotherapy cycles of NPC | Â | Â | 0.390 |
 <3 | 10 (66.7%) | 13 (86.7%) |  |
 ≥3 | 5 (33.3%) | 2 (13.3%) |  |
Pre-resection/TACE comorbidities | Â | Â | Â |
 Present | 3 (20%) | 4 (26.7%) | >0.999 |
 Absent | 12 (80%) | 11 (73.3%) |  |
Post-resection/TACE comorbidities | Â | Â | 0.651 |
 Present | 2 (13.3%) | 4 (26.7%) |  |
 Absent | 13 (86.7%) | 11 (73.3%) |  |
Hospital mortality | 0 (0%) | 0 (0%) | >0.999 |